Cystinuria is an inherited renal and intestinal disease characterized by defective amino acids reabsorption and cystine urolithiasis. It is unusually associated with neurologic symptoms. Mutations in two genes, SLC3A1 and SLC7A9, have been identified in cystinuric patients. This report presents a 13-yr-old boy with cystinuria who manifested difficulty in walking, ataxia, and mental retardation. Somatosensory evoked potential of posterior tibial nerve stimulation showed the central conduction dysfunction through the posterior column of spinal cord. He was diagnosed non-type I cystinuria by urinary amino acid analysis and oral cystine loading test. We screened him and his family for gene mutation by direct sequencing of SLC3A1 and SLC7A9 genes. In this patient, we identified new missence mutation G173R in SLC7A9 gene.
Adolescent ; Amino Acid Substitution ; Amino Acid Transport Systems, Basic/*genetics ; Amino Acids/urine ; Ataxia/complications/diagnosis/*genetics ; Base Sequence ; Cystine/blood ; Cystinuria/complications/diagnosis/*genetics ; Humans ; Intellectual Disability/complications/diagnosis/*genetics ; Male ; *Mutation, Missense ; Pedigree ; Republic of Korea

Amino Acid Transport Systems, Basic ; genetics ; Brain Diseases ; diagnosis ; etiology ; Child ; DNA Mutational Analysis ; Diet, Protein-Restricted ; Female ; Humans ; Hyperammonemia ; complications ; diagnosis ; diet therapy ; genetics ; Ornithine ; deficiency ; genetics ; Recurrence ; Severity of Illness Index ; Urea Cycle Disorders, Inborn ; complications ; diagnosis ; diet therapy ; genetics

The activity of the mTOR pathway is frequently increased in acute myeloid leukemia, and is tightly related with cellular proliferation. Leucine is tightly linked to the mTOR pathway and can activate it, thereby stimulating cellular proliferation. LAT3 is a major transporter for leucine, and suppression of its expression can reduce cell proliferation. Here, we show that suppression of LAT3 expression can reduce proliferation of the acute leukemia cell line, K562. We investigated the mRNA and protein expression of LAT3 in several leukemia cell lines and normal peripheral blood mononuclear cells (PBMNCs) using RT-PCR and Western blotting. We also evaluated cell viability using a methyl thiazolyl tetrazolium (MTT) assay after blocking LAT3 expression with either shRNA targeted to LAT3 or a small molecular inhibitor BCH (2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid). LAT3 mRNA and protein expression was detected in leukemia cell lines, but not in normal PBMNCs. Using K562 cells, it was found that cellular proliferation and mTOR pathway activity were significantly reduced when LAT3 was blocked with either shRNA or BCH. Our results suggest that leukemia cell proliferation can be significantly suppressed by blocking LAT3. This finding may lead to a new strategy to develop clinical therapy for the treatment of acute myeloid leukemia.
Amino Acid Transport Systems, Basic ; antagonists & inhibitors ; genetics ; metabolism ; Amino Acids, Cyclic ; pharmacology ; Blotting, Western ; Cell Line, Tumor ; Cell Proliferation ; Cell Survival ; drug effects ; genetics ; Cells, Cultured ; Dose-Response Relationship, Drug ; Gene Expression Regulation, Leukemic ; genetics ; HL-60 Cells ; Humans ; Jurkat Cells ; K562 Cells ; Leukemia, Erythroblastic, Acute ; genetics ; metabolism ; pathology ; Phosphorylation ; drug effects ; RNA Interference ; Reverse Transcriptase Polymerase Chain Reaction ; TOR Serine-Threonine Kinases ; metabolism